Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
1. Hims is closing Apostrophe, its dermatology unit acquired in 2021. 2. This aims to streamline teledermatology services for better customer access. 3. The stock fluctuated due to pressures on its weight-loss business. 4. FDA's end of semaglutide shortage impacts weight-loss drug availability. 5. Hims expects significant revenue from weight-loss services despite setbacks.